CVM Share Price | CEL-SCI Corp. Stock Analysis & Recommendation

Q: What does CEL-SCI Corp. do?

Overview:CEL-SCI Corporation is engaged in the research and development of cancer treatments and other diseases by utilizing the immune system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025)Market cap: USD 11.91 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: 0.05Return on Equity: -341.14%Price to Book: 1.49Contact Details:Address: 8229 Boone Blvd Ste 802, VIENNA VA: 22182-2634Tel: 1 703 5069460Fax: 1 703 5069471Website: http://www.cel-sci.com/

Q: Is CEL-SCI Corp. technically bullish or bearish?

As of 2 September 2025, the technical trend for CEL-SCI Corp. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a mildly bearish stance. The Bollinger Bands show a mixed signal with a mildly bullish weekly and a bearish monthly. The KST is bullish on a weekly basis but bearish monthly, while Dow Theory indicates a mildly bearish weekly trend with no trend monthly. In terms of performance, CEL-SCI Corp. has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -25.65% compared to the S&P 500's 12.22%, and a one-year return of -73.45% versus 17.14% for the benchmark. Overall, the current technical stance is mildly bearish.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

39.91 k

Shareholding (Dec 2025)

FII

0.84%

Held by 14 FIIs

DII

94.42%

Held by 5 DIIs

Promoter

0.00%

How big is CEL-SCI Corp.?

22-Jun-2025

As of Jun 18, CEL-SCI Corp. has a market capitalization of 11.91 million, with net sales of 0.00 million and a net profit of -26.61 million over the latest four quarters. As of Sep 24, the company reports shareholder's funds of 12.87 million and total assets of 26.99 million.

View full answer

What does CEL-SCI Corp. do?

22-Jun-2025

CEL-SCI Corporation focuses on researching and developing cancer treatments and other diseases by harnessing the immune system, operating as a micro-cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported a net profit loss of $7 million and has a market cap of $11.91 million.

View full answer

Who are in the management team of CEL-SCI Corp.?

22-Jun-2025

As of March 2022, the management team of CEL-SCI Corp. includes CEO Geert Kersten, along with independent directors Bruno Baillavoine, Robert Watson, and Peter Young.

View full answer

Is CEL-SCI Corp. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, CEL-SCI Corp. shows a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, reflecting a year-to-date return of -25.65% versus the S&P's 12.22%.

View full answer

Compare CEL-SCI Corp. with Similar Stocks

Intensity Therapeutics, Inc.Spero Therapeutics, Inc.Shattuck Labs, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 30 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.34

Return on Equity

-222.34%

Price to Book

2.68

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-21.62%

6 Months

-59.68%

1 Year

-55.38%

2 Years

-93.66%

3 Years

60.37%

4 Years

-97.22%

5 Years

-99.32%

CEL-SCI Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-15.10%

EBIT Growth (5y)

2.73%

EBIT to Interest (avg)

-21.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

28.64%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.68

EV to EBIT

-1.12

EV to EBITDA

-1.34

EV to Capital Employed

3.54

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-315.68%

ROE (Latest)

-222.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 8 Schemes (4.74%)

Foreign Institutions

Held by 14 Foreign Institutions (0.84%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 22.54% vs -5.97% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.40",
          "val2": "-5.90",
          "chgp": "25.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-7.10",
          "chgp": "22.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is 5.58% vs 16.46% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-20.90",
          "val2": "-22.40",
          "chgp": "6.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.70",
          "chgp": "-14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.40",
          "val2": "-26.90",
          "chgp": "5.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.40

-5.90

25.42%

Interest

0.10

0.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

-5.50

-7.10

22.54%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 22.54% vs -5.97% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-20.90

-22.40

6.70%

Interest

0.60

0.70

-14.29%

Exceptional Items

0.00

Consolidate Net Profit

-25.40

-26.90

5.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is 5.58% vs 16.46% in Sep 2024

All Annual Results

Company CV

About CEL-SCI Corp.

CEL-SCI Corp.

Pharmaceuticals & Biotechnology

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Company Coordinates

Company Details

8229 Boone Blvd Ste 802 , VIENNA VA : 22182-2634

Tel: 1 703 5069460

http://www.cel-sci.com/

Registrar Details